1
|
Faustova M, Nikolskaya E, Sokol M, Fomicheva M, Petrov R, Yabbarov N. Metalloporphyrins in Medicine: From History to Recent Trends. ACS APPLIED BIO MATERIALS 2020; 3:8146-8171. [PMID: 35019597 DOI: 10.1021/acsabm.0c00941] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The history of metalloporphyrins dates back more than 200 years ago. Metalloporphyrins are excellent catalysts, capable of forming supramolecular systems, participate in oxygen photosynthesis, transport, and used as contrast agents or superoxide dismutase mimetics. Today, metalloporphyrins represent complexes of conjugated π-electron system and metals from the entire periodic system. However, the effect of these compounds on living systems has not been fully understood, and researchers are exploring the properties of metalloporphyrins thereby extending their further application. This review provides an overview of the variety of metalloporphyrins that are currently used in different medicine fields and how metalloporphyrins became the subject of scientists' interest. Currently, metalloporphyrins utilization has expanded significantly, which gave us an opprotunuty to summarize recent progress in metalloporphyrins derivatives and prospects of their application in the treatment and diagnosis of different diseases.
Collapse
Affiliation(s)
- Mariia Faustova
- MIREA-Russian Technological University, Lomonosov Institute of Fine Chemical Technologies, 119454 Moscow, Russia.,N. M. Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, 119991 Moscow, Russia
| | - Elena Nikolskaya
- N. M. Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, 119991 Moscow, Russia
| | - Maria Sokol
- N. M. Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, 119991 Moscow, Russia.,JSC Russian Research Center for Molecular Diagnostics and Therapy, 117149 Moscow Russia
| | - Margarita Fomicheva
- N. M. Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, 119991 Moscow, Russia.,JSC Russian Research Center for Molecular Diagnostics and Therapy, 117149 Moscow Russia
| | - Rem Petrov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow 117997, Russia
| | - Nikita Yabbarov
- N. M. Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, 119991 Moscow, Russia.,JSC Russian Research Center for Molecular Diagnostics and Therapy, 117149 Moscow Russia
| |
Collapse
|
2
|
Yap SY, Savoie H, Renard I, Burke BP, Sample HC, Michue-Seijas S, Archibald SJ, Boyle RW, Stasiuk GJ. Synthesis of a porphyrin with histidine-like chelate: an efficient path towards molecular PDT/SPECT theranostics. Chem Commun (Camb) 2020; 56:11090-11093. [PMID: 32812554 DOI: 10.1039/d0cc03958f] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The goal of "personalised" medicine has seen a growing interest in the development of theranostic agents. Bifunctional, and targeted-trifunctional, theranostic water-soluble porphyrins with a histidine-like chelating group have been synthesised via copper-catalysed azide-alkyne cycloaddition (CuAAC) "click" chemistry in high yield and purity. They are capable of photodynamic treatment and [99mTc(CO)3]+ complexation for single-photon emission computed tomography (SPECT) imaging, with a radiochemical yield of >95%. The toxicity and phototoxicity were evaluated on HT-29 cells, DU145, and DU145-PSMA cell lines, with the targeted theranostic showing more potent phototoxicity towards DU145-PSMA expressing cells.
Collapse
Affiliation(s)
- Steven Y Yap
- Department of Chemistry and Biochemistry, Faculty of Science and Engineering, University of Hull, HU6 7RX, UK.
| | - Huguette Savoie
- Department of Chemistry and Biochemistry, Faculty of Science and Engineering, University of Hull, HU6 7RX, UK.
| | - Isaline Renard
- Department of Biomedical Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK and Positron Emission Tomography Research Centre, University of Hull, Cottingham Road, Hull, HU6 7RX, UK
| | - Benjamin P Burke
- Department of Biomedical Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK and Positron Emission Tomography Research Centre, University of Hull, Cottingham Road, Hull, HU6 7RX, UK
| | - Harry C Sample
- Department of Chemistry and Biochemistry, Faculty of Science and Engineering, University of Hull, HU6 7RX, UK.
| | - Saul Michue-Seijas
- Department of Chemistry and Biochemistry, Faculty of Science and Engineering, University of Hull, HU6 7RX, UK.
| | - Stephen J Archibald
- Department of Biomedical Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK and Positron Emission Tomography Research Centre, University of Hull, Cottingham Road, Hull, HU6 7RX, UK
| | - Ross W Boyle
- Department of Chemistry and Biochemistry, Faculty of Science and Engineering, University of Hull, HU6 7RX, UK.
| | - Graeme J Stasiuk
- Department of Biomedical Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK and Department of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, Fourth Floor Lambeth Wing, St Thomas' Hospital, London SE1 7EH, UK.
| |
Collapse
|
3
|
Song H, Wang G, Wang J, Wang Y, Wei H, He J, Luo S. 131I-labeled 5,10,15,20-tetrakis(4-hydroxyphenyl)porphyrin and 5,10,15,20-tetrakis(4-aminophenyl)porphyrin for combined photodynamic and radionuclide therapy. J Radioanal Nucl Chem 2018. [DOI: 10.1007/s10967-018-5735-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
4
|
Nuclear medicine for photodynamic therapy in cancer: Planning, monitoring and nuclear PDT. Photodiagnosis Photodyn Ther 2017; 18:236-243. [PMID: 28300723 DOI: 10.1016/j.pdpdt.2017.03.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Revised: 02/27/2017] [Accepted: 03/09/2017] [Indexed: 12/16/2022]
Abstract
Photodynamic therapy (PDT) is a modality with promising results for the treatment of various cancers. PDT is increasingly included in the standard of care for different pathologies. This therapy relies on the effects of light delivered to photosensitized cells. At different stages of delivery, PDT requires imaging to plan, evaluate and monitor treatment. The contribution of molecular imaging in this context is important and continues to increase. In this article, we review the contribution of nuclear medicine imaging in oncology to PDT for planning and therapeutic monitoring purposes. Several solutions have been proposed to plan PDT from nuclear medicine imaging. For instance, photosensitizer biodistribution has been evaluated with a radiolabeled photosensitizer or with conventional radiopharmaceuticals on positron emission tomography. The effects of PDT delivery have also been explored with specific SPECT or PET radiopharmaceuticals to evaluate the effects on cells (apoptosis, necrosis, proliferation, metabolism) or vascular damage. Finally, the synergy between photosensitizers and radiopharmaceuticals has been studied considering the Cerenkov effect to activate photosensitized cells.
Collapse
|